IDRA-21
IDRA-21 is an experimental positive allosteric modulator of AMPA receptors. Published evidence is preclinical. A hippocampal ischemia model also found worsened neuronal injury, so cognition findings must not be presented without the neurotoxicity signal.
Pharmacokinetic model
A route-level PK model for idra-21 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Experimental AMPA Modulator
- Suggested cadence
- once daily
Research behind this entry
-
The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys
Oral IDRA-21 improved delayed-matching task accuracy in young and aged rhesus monkeys across 0.15-10 mg/kg, with some effects lasting 48 hours. This was a nonhuman-primate behavioral experiment and did not establish…
-
The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury
In an experimental hippocampal ischemia model, IDRA-21 enhanced neuronal injury. This preclinical hazard signal is directly relevant to an AMPA positive modulator and prevents treating memory-task results as evidence of…
2 published studies referenced in the app, each with a plain-language summary.